Effects of Fluvastatin in Type 2 Diabetic Patients with Hyperlipidemia: Reduction in Cholesterol Oxidation Products and VCAM-1
-
- Guan Jing-Zhi
- Third Department of Internal Medicine, Hirosaki University School of Medicine
-
- Murakami Hiroshi
- Third Department of Internal Medicine, Hirosaki University School of Medicine
-
- Yamato Kazumi
- Third Department of Internal Medicine, Hirosaki University School of Medicine
-
- Tanabe Jutaro
- Third Department of Internal Medicine, Hirosaki University School of Medicine
-
- Matsui Jun
- Third Department of Internal Medicine, Hirosaki University School of Medicine
-
- Tamasawa Naoki
- Third Department of Internal Medicine, Hirosaki University School of Medicine
-
- Suda Toshihiro
- Third Department of Internal Medicine, Hirosaki University School of Medicine
この論文をさがす
抄録
The purpose of this study was to investigate the lipid-lowering and anti-oxidative effects of fluvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, in type 2 diabetic patients. Six patients (3 men and 3 women, mean age = 56.2) took 20 mg of fluvastatin once daily (at night) for 12 weeks. Several markers of oxidative stress were then measured in these patients including plasma cholesterol oxidation products, i.e. oxysterols, and the levels of circulating adhesion molecules. Plasma total cholesterol levels were reduced by 12.3% in these individuals after 4 weeks of treatment, with levels remaining below 220 mg/dl for the entire treatment period. LDL levels were significantly reduced at 4 (18.1%) and 12 weeks (16.1%), and triglyceride levels were significantly reduced after 8 (22.5%) and 12 (37.7%) weeks of treatment. HDL-C levels increased from 50.7 ± 15.4 prior to treatment to 63.8 ± 24.3 mg/dl after 12 weeks of treatment, though this increase was not statistically significant. Lipid hydroperoxide, thiobarbituric acid-reactive substance (TBARS), and oxysterol levels were also reduced, suggesting that fluvastatin also had anti-oxidative effects. Finally, VCAM-1 levels were similarly reduced by fluvastatin treatment. We conclude that fluvastatin safely improves the plasma lipid profile in type 2 diabetic patients with hyperlipidemia. We speculate that this drug might be doubly effective in reducing atherosclerosis and cardiac events in these patients as a result of its demonstrated anti-oxidative effects and its ability to reduce VCAM-1 levels.
収録刊行物
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis 11 (2), 56-61, 2004
一般社団法人 日本動脈硬化学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679409586688
-
- NII論文ID
- 130004444095
- 50000483226
-
- NII書誌ID
- AA11018976
-
- ISSN
- 18803873
- 13403478
-
- PubMed
- 15153664
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可